SS-31 10-50 mg – 10 Vial Box

Description

Description

SS-31 (Elamipretide) is a synthetic tetrapeptide investigated for its interactions with inner mitochondrial membrane cardiolipin and its observed effects on electron transport chain efficiency and reactive oxygen species (ROS) modulation. It has been studied for its interactions with mitochondrial membrane potential dynamics, cristae structural integrity, and oxidative phosphorylation pathway activity. Research has examined its effects across various experimental models involving mitochondrial dysfunction and bioenergetic pathway dysregulation.

For Research Use Only. Not for Human Consumption.

Minimum order quantity: one box (10 vials x 10-50 mg, 100-500 mg total). 

Note: Product images show branded labels for illustration purposes only. All peptides are shipped in wholesale, unbranded packaging. You can see an actual example photo of the peptide vials and container above.

Specifications

Additional information

Research

1. Birk, Alexander V., et al. "The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin." Journal of the American Society of Nephrology 24.8 (2013): 1250-1261.
2. Campbell, Matthew D., et al. "Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice." Free Radical Biology and Medicine 134 (2019): 268-281.
3. Zhu, Yuexin, et al. "SS‐31, a mitochondria‐targeting peptide, ameliorates kidney disease." Oxidative Medicine and Cellular Longevity 2022.1 (2022): 1295509.
4. Sweetwyne, Mariya T., et al. "The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age." Kidney international 91.5 (2017): 1126-1145.
5. Chavez, Juan D., et al. "Mitochondrial protein interaction landscape of SS-31." Proceedings of the National Academy of Sciences 117.26 (2020): 15363-15373.
6. Russo, Silvia, et al. "Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice." Scientific Reports 12.1 (2022): 19847.

Testing Docs